We’ve taken a giant step backwards,” remarked Dr. Paul Offit, a leading vaccine scientist, after the abrupt dismissal of the ...

The new vaccine, mNexspike (mRNA-1283), is a step toward next-generation coronavirus vaccines. It’s made in a way that allows ...

mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults ...

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has ...

mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, ... (mRNA-1273), with a consistent trend observed in the subset of adults age 65 and older.

The mRNA-1345 vaccine should be available in the U.S. for the 2024-2025 ... The vaccine also uses the same lipid nanoparticles as the Moderna's mRNA-1273 vaccine. In 2023, the FDA approved two ...

COVID-19 vaccine development paves way to a new class of cancer immunotherapy. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. For the ...

The Phase I clinical trial utilized Moderna’s commercialized SARS-CoV-2 mRNA vaccine Spikevax (mRNA-1273 and mRNA-1273.222) as the positive control to assess the safety, reactogenicity, and ...

A total of 772,908,958 doses of mRNA-1273 were administered to individuals across 91 countries during the study period. In total, 2,517,669 AEs were reported following vaccination.

At the same time, the National Academies of Sciences, Engineering, and Medicine (NASEM) committee rejected a causal relationship between the Pfizer-BioNTech BNT162b2 and Moderna mRNA-1273 ...

Overall, vaccine efficacy of 2 mRNA-1273 doses against COVID-19 infection was 52.6% (95% CI, -14.1 to 80.3).. The highest overall incidence of COVID-19 infection was observed among patients in the ...

Two mRNA-1273 vaccine doses reduced the incidence of COVID-19 infection in younger adults, though factors beyond vaccination may have contributed to infection risk.